- Home
- EXTR vs MIRM Comparison
EXTR vs MIRM Comparison
Compare EXTR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXTR | MIRM |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 5.7B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EXTR | MIRM |
|---|---|---|
| Price | $23.52 | $96.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $21.20 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 3.3M | 928.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | 74.59 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,140,067,000.00 | $19,138,000.00 |
| Revenue This Year | $13.33 | $26.22 |
| Revenue Next Year | $7.97 | $22.04 |
| P/E Ratio | $130.14 | ★ N/A |
| Revenue Growth | ★ 2.05 | N/A |
| 52 Week Low | $13.48 | $42.89 |
| 52 Week High | $25.13 | $114.99 |
Technical Indicators
Market Signals| Indicator | EXTR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 44.83 |
| Support Level | $22.33 | $87.26 |
| Resistance Level | N/A | $98.03 |
| Average True Range (ATR) | 0.94 | 7.18 |
| MACD | -0.12 | -1.22 |
| Stochastic Oscillator | 52.19 | 29.92 |
Price Performance
Historical ComparisonAbout EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.